The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Integrated analysis of tissue genomic sequencing and high purity circulating tumor cell RNA sequencing for prostate cancer lineage states as a prognostic factor for survival and resistance to 177Lu-PSMA-617 in patients with metastatic castrate resistant prostate cancer.
 
Marina Sharifi
Research Funding - Novartis (Inst)
 
Jamie Sperger
No Relationships to Disclose
 
Amy Taylor
No Relationships to Disclose
 
Katharine Tippins
No Relationships to Disclose
 
Jennifer Schehr
No Relationships to Disclose
 
John Floberg
No Relationships to Disclose
 
Christos Kyriakopoulos
Employment - Epic Systems (I)
Stock and Other Ownership Interests - Biogen; Epic Systems (I)
Consulting or Advisory Role - AVEO; EMD Serono; Exelixis; Janssen Oncology; Pfizer; Sanofi
Research Funding - AstraZeneca; Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); ESSA; Gilead Sciences; Madison Vaccines, Inc. (Inst); Pionyr; Sanofi
 
Hamid Emamekhoo
Consulting or Advisory Role - Bristol Myers Squibb company; Cardinal Health; Cardinal Health; Eisai; Janssen Biotech
 
Scott Tagawa
Stock and Other Ownership Interests - Convergent Therapeutics
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Ambrx; Amgen; Astellas Pharma; Bayer; Bicycle Therapeutics; Blue Earth Diagnostics; Boston Scientific; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Daiichi Sankyo; Dendreon; Endocyte; Exelixis; Genentech; General Electric; Genomic Health; Gilead Sciences; Hookipa Pharma; Immunomedics; Janssen; Karyopharm Therapeutics; Lantheus Medical Imaging; Medivation; Merck; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Regeneron; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar; TransThera Biosciences
Research Funding - Abbvie (Inst); Ambrx (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clarity Pharmaceuticals (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Janux Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst); Telix Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Immunomedics; Merck; Sanofi; Telix Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics
 
Atish Choudhury
Employment - LeMaitre Vascular (I)
Honoraria - Aptitude Health; Color Genomics; DAVA Oncology; Great Debates and Updates; Lantheus Medical Imaging; Medscape; OncLive; Outcomes4Me; Pfizer; Physicans' Education Resource; Springer; Targeted Oncology; Wiley
Consulting or Advisory Role - Astellas Pharma; Bayer; Boundless Bio; Daiichi Sankyo; Janssen Oncology; Johnson & Johnson/Janssen; Pfizer; Pfizer; Sanofi/Aventis; Tolmar; Tolmar
Research Funding - Bayer (Inst); Lilly (Inst); Pfizer (Inst); Pfizer (Inst); Sumitomo Pharma Oncology (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer
 
Andrew Armstrong
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Cytogen; Exelixis; GoodRx; Janssen; Merck; Myovant Sciences; Novartis; Pfizer
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Syntrix Biosystems (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc
 
Dana Rathkopf
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Celgene; Genentech; Janssen; Myovant Sciences; Novartis; Promontory
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb/Celgene (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Novartis (Inst); Promontory Therapeutics (Inst)
 
Himisha Beltran
Consulting or Advisory Role - AstraZeneca; Bayer; Daicchi Sankyo; Merck; Novartis; Pfizer; Sanofi
Research Funding - Bristol Myers Squibb Foundation (Inst); Circle Pharma (Inst); Daiichi Sankyo (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
Peter Nelson
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Genentech; Janssen Oncology; Pfizer
Research Funding - Janssen Oncology
Expert Testimony - Venable
 
Scott Dehm
Consulting or Advisory Role - Celgene; Oncternal Therapeutics
Patents, Royalties, Other Intellectual Property - Royalties from licensing genome-engineered prostate cancer cell lines
Travel, Accommodations, Expenses - Oncternal Therapeutics
 
David Kosoff
No Relationships to Disclose
 
Xiao Wei
Honoraria - OncLive
Consulting or Advisory Role - Dendreon; Novartis; Novartis; Novartis; Novartis
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Corvus Pharmaceuticals; Novartis
 
Rana McKay
Consulting or Advisory Role - Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol Myers Squibb; Calithera Biosciences; Caris Life Sciences; Daiichi Sankyo; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; NeoMorph; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)
 
Shuang Zhao
Employment - Artera (I)
Stock and Other Ownership Interests - Exact Sciences (I)
Patents, Royalties, Other Intellectual Property - Patent applications pending (Inst); Patent applications pending licensed to Veracyte (Inst)
 
Joshua Lang
Consulting or Advisory Role - 4D Pharma; 4D Pharma; Arvinas; AstraZeneca; Foundation Medicine; Gilead Sciences; Immunomedics; Janssen; Macrogenics; Pfizer; Pfizer/Astellas; Pfizer/Myovant; Sanofi
Research Funding - Agensys (Inst); Arvinas (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Medivation (Inst)
Patents, Royalties, Other Intellectual Property - I am listed on the patent on a technology for rare cell capture and analysis. This technology has been licensed by Salus Discovery, LLC though no commercial products are available.